Literature DB >> 12645651

Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma?

R L Stallings1, J Howard, A Dunlop, M Mullarkey, M McDermott, F Breatnach, A O'Meara.   

Abstract

Neuroblastoma exhibiting deletion of a segment of the long arm of chromosome 11 represents a genetic subtype of tumor that is distinct from those exhibiting MYCN amplification or 1p deletion. The 11q- genetic subtype is further characterized by gain of 17q and loss of distal 3p material. Gain of 11p material has also been reported in neuroblastoma with 11q loss, but at a considerably lower frequency than gain of 17q or loss of the distal 3p region. Our results, however, indicate that gain of 11p may occur more frequently in 11q- neuroblastoma than what was previously realized. Comparative genomic hybridization analyses of neuroblastoma tissue from eleven patients indicated that six of 11 tumors (55%) with loss of 11q also possessed gain of 11p. The shortest region of 11p gain was 11p11.2-->p14. G-banding and fluorescence in situ hybridization analysis performed on tumor cells from primary and metastatic sites from one patient allowed us to infer that gain of 11p arose secondarily to the abnormality that led to the loss of 11q material. Gain of an entire chromosome 7 was detected in 17 of 43 (40%) tumors, whereas gain of 7q was detected in 5 of 43 (12%) tumors. Unlike gain of 11p, gain of an entire chromosome 7 appears to be prevalent in all tumor stages and is not limited to the 11q- tumor subtype. Gain of 7q, however, is more prevalent in higher stage tumors. G-band cytogenetic analysis indicated that an unbalanced t(3;7) was responsible for the gain of 7q and loss of 3p material in one case. We discuss the possibility that gain of 7/7q, and 11p material may contribute to either tumorigenesis or progression.

Entities:  

Mesh:

Year:  2003        PMID: 12645651     DOI: 10.1016/s0165-4608(02)00681-7

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  9 in total

1.  EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.

Authors:  Chunxi Wang; Zhihui Liu; Chan-Wook Woo; Zhijie Li; Lifeng Wang; Jun S Wei; Victor E Marquez; Susan E Bates; Qihuang Jin; Javed Khan; Kai Ge; Carol J Thiele
Journal:  Cancer Res       Date:  2011-11-08       Impact factor: 12.701

2.  MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma.

Authors:  Isabella Bray; Amanda Tivnan; Kenneth Bryan; Niamh H Foley; Karen M Watters; Lorraine Tracey; Andrew M Davidoff; Raymond L Stallings
Journal:  Cancer Lett       Date:  2011-04-01       Impact factor: 8.679

3.  MicroRNA-184-mediated inhibition of tumour growth in an orthotopic murine model of neuroblastoma.

Authors:  Amanda Tivnan; Niamh H Foley; Lorraine Tracey; Andrew M Davidoff; Raymond L Stallings
Journal:  Anticancer Res       Date:  2010-11       Impact factor: 2.480

Review 4.  Epigenetic changes in pediatric solid tumors: promising new targets.

Authors:  Elizabeth R Lawlor; Carol J Thiele
Journal:  Clin Cancer Res       Date:  2012-05-15       Impact factor: 12.531

5.  Novel DNA amplification on chromosomes 2p25.3 and 7q11.23 in cholangiocarcinoma identified by arbitrarily primed polymerase chain reaction.

Authors:  S Chariyalertsak; T Khuhaprema; V Bhudisawasdi; B Sripa; S Wongkham; S Petmitr
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-15       Impact factor: 4.322

6.  Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays.

Authors:  Rani E George; Edward F Attiyeh; Shuli Li; Lisa A Moreau; Donna Neuberg; Cheng Li; Edward A Fox; Matthew Meyerson; Lisa Diller; Paolo Fortina; A Thomas Look; John M Maris
Journal:  PLoS One       Date:  2007-02-28       Impact factor: 3.240

7.  Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions.

Authors:  Karin Schmelz; Joern Toedling; Matt Huska; Maja C Cwikla; Louisa-Marie Kruetzfeldt; Jutta Proba; Peter F Ambros; Inge M Ambros; Sengül Boral; Marco Lodrini; Celine Y Chen; Martin Burkert; Dennis Guergen; Annabell Szymansky; Kathy Astrahantseff; Annette Kuenkele; Kerstin Haase; Matthias Fischer; Hedwig E Deubzer; Falk Hertwig; Patrick Hundsdoerfer; Anton G Henssen; Roland F Schwarz; Johannes H Schulte; Angelika Eggert
Journal:  Nat Commun       Date:  2021-11-23       Impact factor: 14.919

8.  Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.

Authors:  Kristopher R Bosse; Pichai Raman; Zhongyu Zhu; Maria Lane; Daniel Martinez; Sabine Heitzeneder; Komal S Rathi; Nathan M Kendsersky; Michael Randall; Laura Donovan; Sorana Morrissy; Robyn T Sussman; Doncho V Zhelev; Yang Feng; Yanping Wang; Jennifer Hwang; Gonzalo Lopez; Jo Lynne Harenza; Jun S Wei; Bruce Pawel; Tricia Bhatti; Mariarita Santi; Arupa Ganguly; Javed Khan; Marco A Marra; Michael D Taylor; Dimiter S Dimitrov; Crystal L Mackall; John M Maris
Journal:  Cancer Cell       Date:  2017-09-11       Impact factor: 38.585

9.  A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.

Authors:  K Althoff; A Beckers; E Bell; M Nortmeyer; T Thor; A Sprüssel; S Lindner; K De Preter; A Florin; L C Heukamp; L Klein-Hitpass; K Astrahantseff; C Kumps; F Speleman; A Eggert; F Westermann; A Schramm; J H Schulte
Journal:  Oncogene       Date:  2014-09-01       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.